🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07079085
Starting soon Observational

Safety Evaluation of Pueraria Lobata Radix in Specific Consumption Scenarios for Type 2 Diabetes

NCT07079085 · tracked via the Priya Life Science China tracker
Sponsor
Jiangxi University of Traditional Chinese Medicine
Phase
Observational
Started
2025-08-01
Last updated
2025-07-22

Condition(s) studied

Type 2 Diabetes

Study summary

This real-world study aims to investigate the association between the consumption of Pueraria lobata radix and adverse events in patients with type 2 diabetes mellitus (T2DM) under special scenarios. By retrospectively analyzing the clinical data of patients with T2DM, we will evaluate the safety profile of Pueraria lobata radix in different special populations, identify potential risk factors, and provide evidence-based support for the safe consumption and clinical use of Pueraria lobata radix.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Diagnosis with T2DM. 2. Documented history of consuming Pueraria lobata radix (PLR) in any dosage form (e.g., dried slices, root cubes). 3. Fulfillment of at least one of the following special scenarios: 1) Excessive dosage: Daily PLR intake ≥ twice the maximum dose specified in the Chinese Pharmacopoeia; 2) Long-term consumption: PLR consumption duration ≥ three months with frequency ≥ three times weekly; 3) Advanced age: ≥ 80 years; 4) Pregnancy; 5) Lactation; 6) Allergic constitution: History of any food or drug allergy; 7) Liver dysfunction: Clinical diagnosis of liver cirrhosis or chronic liver failure, or laboratory findings of total bilirubin \> 1.5 × upper limit of normal (ULN) or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) \> 2 × ULN; 8) Renal insufficiency: Clinical diagnosis of diabetic nephropathy or chronic nephritis with renal function impairment, or serum creatinine \> 120% of ULN. 4. Occurrence of adverse events during the retrospective observation period within one month following PLR consumption. Exclusion Criteria: 1. Diagnosis of type 1 diabetes mellitus, gestational diabetes mellitus, or other specific types of diabetes. 2. Use of PLR compound preparations (e.g., puerarin injection). 3. Unavailability of complete clinical data or patient refusal to provide essential information required for the observation period during follow-up.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine Nanchang Jiangxi

More Jiangxi University of Traditional Chinese Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07079085 on ClinicalTrials.gov ↗ ← All trials in China